Breast Cancer
SERENA-6
About the SERENA-6 Trial
Table of Contents
Major Presentations and Milestones
SERENA-6 Trial design, results, and conclusions
SERENA-6 Sentiments and Criticisms
SERENA-6 Temporal Sentiment Arc
SERENA-6 Trial: Major Presentations and Milestones
Primary speakers driving the story
Discussion around SERENA-6 accelerated in early 2025 as clinicians framed the study as a potential “resistance interception” strategy: monitoring for emergent ESR1 mutations on first-line AI + CDK4/6 inhibitor and switching endocrine backbone to camizestrant before radiographic/clinical progression. Sara Tolaney, MD (Dana-Farber Cancer Institute) captured this framing succinctly: “SERENA-6: ctDNA guided approach to switching from AI to camizestrant upon development of ESR1m in combo with cdk4/6i demonstrates improvement in PFS! … Could be a paradigm shift + could introduce ctDNA monitoring into practice.” https://x.com/stolaney1/status/1894714234623197260
At ASCO 2025, the trial’s main-stage visibility was reinforced by society and journal amplification. NEJM highlighted the central message: “switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival.” https://x.com/NEJM/status/1929147672373702906
Presented at #ASCO25:
— NEJM (@NEJM) Jun 1, 2025
In patients with advanced breast cancer, switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival. Full SERENA-6 phase 3 trial results: https://t.co/bAa7fsay28
Several KOLs also pointed to structured “takeaways” content as the community tried to translate the results into practice. Harold J. Burstein, MD, PhD, FASCO (Dana-Farber Cancer Institute) posted: “SERENA-6 trial takeaways from @AngieDemichele.” https://x.com/DrHBurstein/status/1929265891520217143
SERENA-6 Trial Design, Results, and Conclusions
Trial Design:
Based on clinician summaries in the dataset, SERENA-6 is a phase 3 strategy trial in HR-positive, HER2-negative advanced breast cancer testing a ctDNA-guided switch in endocrine therapy: patients on first-line AI + CDK4/6 inhibitor are monitored for emergent ESR1 mutation, and if detected (before progression), switch to camizestrant + CDK4/6 inhibitor versus continuing AI + CDK4/6 inhibitor. Oncology Brothers summarized: “Camizestrant + CDK4/6i vs AI + CDK4/6i for emerging ESR1m before progression.” https://x.com/OncBrothers/status/1929316463921209853
Primary Results (PFS):
The consistent cross-tweet message was that the ctDNA-guided switch strategy improves PFS. Sara Tolaney, MD stated it “demonstrates improvement in PFS!” while emphasizing that downstream endpoints were not yet mature. https://x.com/stolaney1/status/1894714234623197260
NEJM’s meeting post similarly emphasized “significantly longer progression-free survival” with the switch to camizestrant + CDK4/6 inhibitor upon ESR1 mutation detection. https://x.com/NEJM/status/1929147672373702906
Time on 1L therapy / clinical meaning of the PFS gain:
Paolo Tarantino, MD framed the practical interpretation as prolonging time on first-line therapy: “a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts on 1L treatment for 6.9 months longer.” He also cautioned: “What it does not show (yet): that this strategy improves long term outcomes.” https://x.com/PTarantinoMD/status/1929267181373501616
SERENA6 presentation by Nick Turner. What it shows: that a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts on 1L treatment for 6.9 months longer. What it does not show (yet): that this strategy improves long term outcomes. @NEJM publication: https://t.co/ti0EnlW355 https://t.co/a7ezuvbQrI
— Paolo Tarantino (@PTarantinoMD) Jun 1, 2025
Key secondary endpoints (immature):
Across tweets, KOLs repeatedly highlighted immaturity of longer-horizon endpoints. Sara Tolaney, MD: “PFS2 + OS immature.” https://x.com/stolaney1/status/1894714234623197260
Key Conclusions:
In the tweet-level discourse captured here, SERENA-6 is viewed as proof-of-concept for molecular progression–guided endocrine switching that improves PFS and extends time on first-line therapy. However, multiple KOLs emphasized that the trial has not yet established improvement in longer-term outcomes (PFS2/OS), and that design choices (e.g., crossover and how PFS2 is defined) will influence how “practice changing” the strategy ultimately becomes.
SERENA-6 Sentiments and Criticisms
Positive Reception (paradigm/implementation potential):
Sara Tolaney, MD: “SERENA-6: ctDNA guided approach… demonstrates improvement in PFS! … Could be a paradigm shift + could introduce ctDNA monitoring into practice” https://x.com/stolaney1/status/1894714234623197260
NEJM (meeting amplification): “switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection… led to significantly longer progression-free survival.” https://x.com/NEJM/status/1929147672373702906
Critical Perspectives (what the trial does/does not prove yet):
Paolo Tarantino, MD (ASCO 2025): “What it does not show (yet): that this strategy improves long term outcomes.” https://x.com/PTarantinoMD/status/1929267181373501616
Stephanie Graff, MD, FACP, FASCO (ASCO 2025) questioned whether the current maturity of endpoints supports immediate practice change: “PFS-2 is immature and crossover was not allowed; given PFS on postMonarch & EMBER-3 combo, it is unclear to me that early switch based on molecular disease is practice changing.” https://x.com/DrSGraff/status/1929271418698498166
As anticipated, SERENA-6 creates a lot of questions.
— Stephanie Graff, MD, FACP, FASCO (@DrSGraff) Jun 1, 2025
PFS-2 is immature and crossover was not allowed; given PFS on postMonarch & EMBER-3 combo, it is unclear to me that early switch based on molecular disease is practice changing. #ASCO25 https://t.co/dnUqTLZbGp
Methodologic nuance (PFS2 definition / sequencing imbalance):
Paolo Tarantino, MD relayed a design concern raised by Angie DeMichele, MD: “should PFS2 in SERENA-6 include the post-cami treatment? That creates an imbalance, since it compares patients that received a sequence of 3 treatments to patients that only received 2.” https://x.com/PTarantinoMD/status/1929268164069666990
SERENA-6 Temporal Sentiment Arc
Early 2025 (pre-ASCO: “ctDNA interception” framing)
Primary/KOL tweets:
- https://x.com/stolaney1/status/1894714234623197260
- Tone: Cautious optimism—PFS improvement is viewed as meaningful and the ctDNA-guided approach is framed as potentially paradigm-shifting.
- Shift: Early emphasis on feasibility and the prospect of bringing routine ctDNA monitoring into everyday HR+/HER2− metastatic practice.
June 2025 (ASCO25 + NEJM publication: efficacy signal meets endpoint/design scrutiny)
Primary/KOL tweets:
- https://x.com/NEJM/status/1929147672373702906
- https://x.com/PTarantinoMD/status/1929267181373501616
- https://x.com/PTarantinoMD/status/1929268164069666990
- https://x.com/DrSGraff/status/1929271418698498166
- Tone: Balanced—broad acknowledgement of improved PFS/time on 1L therapy, but increased skepticism about “practice-changing” claims without mature PFS2/OS and with key design constraints (no crossover; PFS2 definition concerns).
- Shift: From “intercept resistance early” to “does earlier switching translate into better long-term outcomes and how should we interpret PFS2?”
Overall, SERENA-6 discourse in this dataset shows a classic arc: early enthusiasm for a precision-monitoring strategy, followed by rigorous endpoint and trial-design interrogation once the data are presented and published.
SERENA-6 Professional Resources
